Yu Cheuk-Man, Zhang Qing, Lam Linda, Lin Hong, Kong Shun-Ling, Chan Wilson, Fung Jeffrey Wing-Hong, Cheng Kenny K K, Chan Iris Hiu-Shuen, Lee Stephen Wai-Luen, Sanderson John E, Lam Christopher Wai-Kei
Division of Cardiology, SH Ho Cardiovascular and Stroke Centre, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.
Heart. 2007 Aug;93(8):933-9. doi: 10.1136/hrt.2006.102848. Epub 2007 Mar 7.
Intensive statin therapy has been shown to improve prognosis in patients with coronary heart disease (CHD). It is unknown whether such benefit is mediated through the reduction of atherosclerotic plaque burden.
To examine the efficacy of high-dose atorvastatin in the reduction of carotid intimal-medial thickness (IMT) and inflammatory markers in patients with CHD.
Randomised trial.
Single centre.
112 patients with angiographic evidence of CHD.
A high dose (80 mg daily) or low dose (10 mg daily) of atorvastatin was given for 26 weeks.
Carotid IMT, C-reactive protein (CRP) and proinflammatory cytokine levels were assessed before and after therapy.
The carotid IMT was reduced significantly in the high-dose group (left: mean (SD), 1.24 (0.48) vs 1.15 (0.35) mm, p = 0.02; right: 1.12 (0.41) vs 1.01 (0.26) mm, p = 0.01), but was unchanged in the low-dose group (left: 1.25 (0.55) vs 1.20 (0.51) mm, p = NS; right: 1.18 (0.54) vs 1.15 (0.41) mm, p = NS). The CRP levels were reduced only in the high-dose group (from 3.92 (6.59) to 1.35 (1.83) mg/l, p = 0.01), but not in the low-dose group (from 2.25 (1.84) to 3.36 (6.15) mg/l, p = NS). A modest correlation was observed between the changes in carotid IMT and CRP (r = 0.21, p = 0.03).
In patients with CHD, intensive atorvastatin therapy results in regression of carotid atherosclerotic disease, which is associated with reduction in CRP levels. On the other hand, a low-dose regimen only prevents progression of the disease.
强化他汀类药物治疗已被证明可改善冠心病(CHD)患者的预后。目前尚不清楚这种益处是否通过减轻动脉粥样硬化斑块负担来介导。
研究大剂量阿托伐他汀对降低冠心病患者颈动脉内膜中层厚度(IMT)和炎症标志物的疗效。
随机试验。
单中心。
112例有冠心病血管造影证据的患者。
给予大剂量(每日80毫克)或小剂量(每日10毫克)阿托伐他汀治疗26周。
治疗前后评估颈动脉IMT、C反应蛋白(CRP)和促炎细胞因子水平。
大剂量组颈动脉IMT显著降低(左侧:均值(标准差),1.24(0.48)对1.15(0.35)毫米,p = 0.02;右侧:1.12(0.41)对1.01(0.26)毫米,p = 0.01),而小剂量组无变化(左侧:1.25(0.55)对1.20(0.51)毫米,p = 无统计学意义;右侧:1.18(0.54)对1.15(0.41)毫米,p = 无统计学意义)。CRP水平仅在大剂量组降低(从3.92(6.59)降至1.35(1.83)毫克/升,p = 0.01),而小剂量组未降低(从2.25(1.84)升至3.36(6.15)毫克/升,p = 无统计学意义)。观察到颈动脉IMT变化与CRP之间存在适度相关性(r = 0.21,p = 0.03)。
在冠心病患者中,强化阿托伐他汀治疗可使颈动脉粥样硬化病变消退,这与CRP水平降低有关。另一方面,小剂量方案仅能预防疾病进展。